Neoadjuvant GW572016 to Treat Breast Cancer

Part of paid clinical trials in Los Angeles, California.

Sponsor
Baylor Breast Care Center
Study ID
NCT00206427
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • GW572016 — DRUG
    Lapatinib, 500 mg
  • lapatinib — DRUG
    Lapatinib 500 mg PO

Study Details

We want to learn whether GW572016 is effective in breast cancers that have HER2.

Key Dates

Start date
Aug 31, 2004
Status verified
Sep 2021
Primary completion
Jun 30, 2011
Completion
Feb 29, 2012

Study Design

Enrollment
49 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Intervention
    Intervention/Lapatinib (GW572016)

Primary Outcome Measure

Clinical Response [ Time Frame: at the end of week 6. ]

Locations (3)

FacilityCityStateZIPSite coordinators
USC Norris Comprehensive Cancer CenterLos AngelesCalifornia90033-
University of New MexicoAlbuquerqueNew Mexico87131-
Baylor Breast CenterHoustonTexas77030-

Find similar trials in Los Angeles, CA

By condition
Breast cancer
By specialty
OncologyBreast oncologyWomen's health
By research site
USC Norris Comprehensive Cancer Center· Los Angeles, CAUniversity of New Mexico· Albuquerque, NMBaylor Breast Center· Houston, TX

Related Studies